Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

BRAF NP_004324.2:p.V600K

Known as: Serine/Threonine-Protein Kinase B-raf Val600Lys, NP_004324.2:p.Val600Lys, BRAF p.Val600Lys 
A change in the amino acid residue at position 600 in the serine/threonine protein kinase B-raf protein where valine has been replaced by lysine.
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
BackgroundThe resistance to PD-1/PD-L1 inhibitors for the treatment of melanoma have prompted investigators to implement novel… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2017
2017
Heterogeneity of BRAF mutation in melanoma has been a controversial subject. Quantitative data on BRAF allele frequency (AF) are… Expand
2017
2017
Studies on melanoma brain metastases (MBM) with regard to mutational status are lacking. We investigated the outcomes of MBM in… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
2017
2017
9541Background: BRAF V600E and V600K/R mm have distinct clinicopathologic features suggesting different etiology. V600K/R mm… Expand
2017
2017
Die Einführung der BRAF-Inhibitoren hat die Therapiemöglichkeiten beim nicht resezierbaren beziehungsweise metastasierten… Expand
2014
2014
  • M. Villanueva
  • Nature Reviews Clinical Oncology
  • 2014
  • Corpus ID: 27219534
In the past few years, the treatment of melanoma has been revolutionised by the approval of the CTLA-4 antibody, ipilimumab, and… Expand
Highly Cited
2013
Highly Cited
2013
BackgroundThe approval of vemurafenib in the US 2011 and in Europe 2012 improved the therapy of not resectable or metastatic… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Highly Cited
2012
Highly Cited
2012
CONTEXT A polymerase chain reaction-based companion diagnostic (cobas 4800 BRAF V600 Mutation Test) was recently approved by the… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
2012
2012
The presence of a BRAF mutation in a melanoma tumor predicts response to BRAF inhibitors; however, the biological characteristics… Expand
Highly Cited
2010
Highly Cited
2010
Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show… Expand
  • table 1
  • figure 1
  • figure 2